Klin Farmakol Farm. 2014;28(2):68-71

Etravirine in clinical practice

David Jilich¹, Hanuš Rozsypal², Alena Zjevíková³, Dalibor Sedláček⁴, Svatava Snopková⁵, Ladislav Machala⁶

¹ Klinika infekčních, tropických a parazitárních nemocí 1. LF UK v Praze a Nemocnice Na Bulovce

² Klinika infekčních, tropických a parazitárních nemocí 1. LF UK v Praze

³ Infekční klinika, FN Ostrava

⁴ Infekční klinika FN Plzeň

⁵ Infekční klinika FN Brno

⁶ Klinika infekčních, tropických a parazitárních nemocí 3. LF UK v Praze a Nemocnice Na Bulovce

Since the mid-nineties of the last century, combination antiretroviral therapy has been the main treatment strategy for HIV. Reverse

transcriptase inhibitors are among the traditionally used drug classes. Etravirine is a second-generation non-nucleoside reverse transcriptase

inhibitor (NNRTI). Due to the need to combine drugs from different classes, each newly approved medicinal product is an option

for patients with resistance or intolerance to previous therapy. Etravirine is generally characterized by high efficacy, a low risk of side

effects and a higher resistance barrier in comparison with first-generation NNRTIs.

Keywords: etravirine, HIV, NNRTI, cART

Published: July 1, 2014  Show citation